Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation

被引：2

作者：

Siniarski, Aleksander ^{[1
]}

Gasecka, Aleksandra ^{[2
,3
]}

Starczynski, Milosz ^{[2
,3
]}

Banaszkiewicz, Marta ^{[4
]}

Darocha, Szymon ^{[4
]}

Torbicki, Adam ^{[4
]}

Kurzyna, Marcin ^{[4
]}

Filipiak, Krzysztof J. ^{[5
]}

Nessler, Jadwiga ^{[1
]}

Gajos, Grzegorz ^{[1
]}

机构：

[1] Jagiellonian Univ Med Coll, John Paul II Hosp, Inst Cardiol, Dept Coronary Artery Dis & Heart Failure, Krakow, Poland

[2] Med Univ Warsaw, Chair 1, Warsaw, Poland

[3] Med Univ Warsaw, Dept Cardiol, Warsaw, Poland

[4] European Hlth Ctr Otwock, Ctr Postgrad Med Educ, Dept Pulm Circulat Thromboembol Dis & Cardiol, Otwock, Poland

[5] Maria Sklodowska Curie Med Acad, Dept Clin Sci, Warsaw, Poland

来源：

PLATELETS | 2022年 / 33卷 / 07期

关键词：

Fibrin clot; fibrinolysis; platelet reactivity; prostacyclin analogues; pulmonary arterial hypertension; thrombin generation; HEART-FAILURE; ILOPROST; ANTICOAGULATION; EPIDEMIOLOGY; INHIBITION; MECHANISMS; EXPRESSION; REACTIVITY; ADHESION; THERAPY;

D O I：

10.1080/09537104.2022.2042234

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Prostacyclin (PGI(2)) analogues (epoprostenol, treprostonil, iloprost) are the cornerstone of pulmonary arterial hypertension (PAH) treatment. PGI(2) analogues inhibit platelet reactivity, but their impact on coagulation and fibrinolysis parameters has not been elucidated. We compared platelet reactivity, thrombin generation, clot permeation, and lysis properties in patients with PAH treated with PGI(2) analogues (n = 20) and those not receiving PGI(2) analogues (n = 20). Platelet reactivity was lower in patients treated with PGI(2) analogues, compared to the control group, as evaluated with arachidonic acid (ASPI), adenosine diphosphate (ADP), and thrombin receptor-activating peptide-6 (TRAP) tests (p = .009, p = .02, p = .007, respectively). In the subgroup analysis, both treprostinil and epoprostenol decreased platelet reactivity to the similar extent. There were no differences regarding thrombin generation, clot permeation, and lysis parameters in patients receiving and not receiving PGI(2) analogues (p >= .60 for all). In the subgroup analysis, there were no differences regarding coagulation and fibrinolysis parameters between treprostinil, epoprostenol, and no PGI(2) analogues. To conclude, patients with PAH treated with PGI(2) analogues have reduced platelet reactivity, but similar clot formation and lysis parameters, compared to patients not receiving PGI(2) analogues. Further randomized clinical trials are required to confirm these findings.

引用

页码：1065 / 1074

页数：10

共 69 条

[1] Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention [J].